Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 1

Status

Completed 23Terminated 6Unknown 5Withdrawn 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Recurrence 8Lymphoma, Non-Hodgkin 6Multiple Myeloma 5Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Neoplasms, Plasma Cell 1Neoplasms, Experimental 1Neoplasms by Histologic Type 1Lymphomatoid Granulomatosis 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Immune System Diseases 1Burkitt Lymphoma 1

Interventions

Dexamethasone 64Cyclophosphamide 40Bortezomib 37Melphalan 24Lenalidomide 23Thalidomide 17pomalidomide 16fludarabine 12daratumumab 11carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6Prednisone 5Peripheral Blood Stem Cell Transplantation 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4isatuximab 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4Calcium Dobesilate 4liposomal doxorubicin 3ixazomib 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Multiple Myeloma × Bendamustine Hydrochloride × Clear all
NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Duke University

Phase 1/2 Unknown
56 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT05006469 2021-08-16

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Shengjing Hospital

Phase 3 Unknown
10 enrolled
Plasma cell

Multiple Myeloma

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Sun Yat-sen University

Phase 1/2 Unknown
56 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01686386 2013-04-05

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Gruppo Italiano Studio Linfomi

Phase 1/2 Unknown
60 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01002703 2011-08-12

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

University of Leipzig

Phase 1/2 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡